In a model system employing Chinese hamster V-79 cells, the DNA synthesis inhibitor 3'-azido-3'-deoxythymidine (BW A509U, AZT) was shown to induce genome-wide DNA hypermethylation, low-frequency silencing of thymidine kinase (TK; EC 2.7.1.21) gene expression, and resistance to AZT. Twenty-four hours of exposure of V-79 cells to 150 ,uM AZT led to >2-fold enhancement of genomic 5-methylcytosine levels and produced TK-epimutants at a rate -43-fold above background. Such AZT-induced TK-epimutants were shown to be severely reduced in their capacity to activate AZT to its proximate antiviral form, AZT 5'-monophosphate, as compared with the TK+ parental cell line from which they were derived. TK-clones isolated under these conditions were shown to be 9-to 24-fold more resistant to the cytotoxic effects of AZT than the parental TK+ cell line and showed collateral resistance to 5-fluoro-2'-deoxyuridine. Three of four TK-epimutants could be reactivated at very high frequency (8-73%) to the TK+ AZT-sensitive phenotype by 24 hr of exposure to the demethylating agent 5-azadeoxycytidine (5-azadC), implying that drug-induced DNA hypermethylation, rather than classical mutation, was involved in the original gene-silencing event in these three clones. These 5-azadC-induced TK+ revertants concomitantly regained the ability to metabolize AZT to its 5'-monophosphate. RNA slot blot analyses indicated that the four AZT-induced TK-clones expressed 8.9%, 15.6%, 17.8%, and 11.1% of the parental level of TK mRNA. The three clones that were reactivatable by 5-azadC showed reexpression of TK mRNA to levels 84.4%, 51.1%, and 80.0% that of the TK+ parental cell line. These experiments show that one potential mechanism of drug resistance involves drug-induced DNA hypermethylation and resulting transcriptional inactivation of cellular genes whose products are required for drug activation.
The usefulness of drugs used in the treatment of cancer and chronic viral infections is frequently limited by the development of clinical drug resistance (1) (2) (3) (4) . 3'-Azido-3'-deoxythymidine (AZT) is a drug with potential anticancer and proven antiviral activity. In a manner similar to the widely used anticancer agent 1-j3-D-arabinofuranosylcytosine (araC), AZT is activated by cellular enzymes to its nucleotide form and then incorporated into DNA during S phase, where it terminates further chain elongation (5) . As an experimental anticancer agent, AZT is used to take advantage of a putative overexpression of enzymes involved in DNA synthesis and repair which may occur as one aspect of the development of resistance to cisplatin (6) (7) (8) . For example, DNA polymerase (Pol) (3, which is primarily involved in the repair of damaged DNA, is apparently less discriminating in its choice of nucleotides than is Pol a, which conducts replicative DNA synthesis with a much higher level of fidelity (9) . Repair tracts within cisplatin-resistant tumor cells expressing elevated levels of Pol 3 may thus tend to be terminated by incorporation of AZT to a greater degree than would similarly exposed normal host tissues (6) (7) (8) . Similarly, cisplatinresistant tumors expressing elevated levels of thymidine kinase (TK), the enzyme responsible for activating AZT to its proximate cytotoxic form, would also be expected to show enhanced sensitivity to AZT (6) .
The potential for AZT as a cancer chemotherapy agent is apparently not limited to tumors expressing resistance to cisplatin. Thus, based upon a similar biochemical rationale, phase I trials are underway studying AZT combined with 5-fluorouracil and leucovorin (10) , and combinations of AZT and 5-fluorouracil, cisplatin, and methotrexate (11) .
A strategy similar to that described above for circumvention of resistance to cisplatin is involved in the use of AZT to limit human immunodeficiency virus type 1 (HIV-1) infection, since the HIV-1 reverse transcriptase (RT) is several orders of magnitude less discriminating in its choice of nucleotides than host Pol a (5, 9) . Recent work on the mechanism underlying the development of clinical resistance to AZT during treatment of AIDS patients has focused upon mutation of the RT gene of HIV-1 (3, 4) . Such mutations are thought to produce an alteration in the RT protein which reduces the extent to which AZT may be used as a substrate in the reverse transcription of the HIV-1 RNA genome into DNA. This model is attractive, since the mutation rate within RNA genomes is many orders of magnitude greater than that within DNA genomes (12) (13) (14) (15) (16) . Based upon analogy with known mechanisms of resistance to closely related agents such as araC (17) , however, cell-mediated mechanisms of acquired resistance to AZT may also exist and may play an important role in the clinical pathobiology of long-term exposure to AZT in both cancer and AIDS patients.
Drug-induced DNA hypermethylation occurs as part of the cellular response to toxic drug exposures that inhibit DNA synthesis (18) (19) (20) (21) . It was suggested that such drug-induced DNA hypermethylation may be capable of silencing genes by transcriptional inactivation and conferring upon cells resistance to drugs requiring metabolic activation by the protein encoded by the silenced gene (19) (20) (21) . Drug-induced DNA hypermethylation is not solely a tissue culture phenomenon, since malignant cells isolated from cancer patients undergoing in vivo exposure to cytotoxic chemotherapy agents (e.g., hydroxyurea, araC) were also found to have undergone genome-wide DNA hypermethylation (21) . In the present work we show that resistance to AZT can occur by AZTinduced DNA hypermethylation which transcriptionally inAbbreviations: araC, 1-13-D-arabinofuranosylcytosine; 5-azadC, 5-aza-2'-deoxycytidine; AZT, 3'-azido-3'-deoxythymidine; AZTMP, AZT 5'-monophosphate; AZTDP, AZT 5'-diphosphate; AZTTP, AZT 5'-triphosphate; BrdUrd, 5-bromo-2'-deoxyuridine; FdUrd, 5-fluoro-2'-deoxyuridine; HAT, hypoxanthine/aminopterin/ thymidine; HIV-1, human immunodeficiency virus type 1; Pol, DNA polymerase; RT, reverse transcriptase; TK, thymidine kinase.
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activates the cellular TK gene, preventing metabolic activation of AZT to its proximate antiviral form, AZT 5'-monophosphate (AZTMP). The AZT-resistant phenotype was observed to be reversible in three of four TK-clones as a result of exposure to the demethylating agent 5-aza-2'-deoxycytidine (5-azadC), indicating an epigenetic rather than mutational basis for this mechanism of acquired resistance to AZT in these clones. Following Jeggo and Holliday (22) , we therefore refer to these hypermethylation-induced clones as "epimutants." We propose that such drug-induced DNA hypermethylation and the subsequent generation of epimutants by potentially reversible gene-silencing events may be an important mechanism of acquired resistance to any drug requiring metabolic activation to elicit a therapeutic effect. and 5-azadC were purchased from Sigma. 5-Methyldeoxycytidine 5'-triphosphate was purchased from Pharmacia. Tissue culture media and other reagents were purchased from Sigma, and fetal bovine serum was obtained from JRH Biosciences (Lenexa, KS).
MATERIALS AND METHODS
Analysis of DNA Hypermethylation. Cells in logarithmic phase (2.5 x 105 per 60-mm tissue culture dish) were exposed to the indicated concentrations of AZT for 48 hr in the presence of [6-3H] uridine (1 ,uCi/ml; 50 Ci/mmol; ICN).
DNA 5-methylcytosine levels were quantitated as described (20) .
Quantitation of TK Gene Silencing and Activation. Following hypermethylating doses of AZT (100 or 150 ,uM for 48 hr) to TK+ parental V-79 cells, the level of TK gene silencing events was quantitated by subsequent continuous exposure to 5-bromo-2'-deoxyuridine (BrdUrd, 100 ,ug/ml). After (1 ,Ci/ml) for 1 hr. After neutralization, trichloroacetic acid-extracted nucleotide pools were directly injected onto a Whatman SAX strong anion-exchange column and eluted under the following conditions: 0-2 min, 90% solvent A/10% solvent B; 2-20 min, a linear gradient to 90%o solvent B. Solvent A consisted ofdeionized ultrapure water, and solvent B consisted of 1 M KH2PO4, pH 5.5. A Bio-Rad gradientmodule HPLC equipped with a model 1706 UV/visible variable wavelength detector (detection performed at 254 nm) was used to establish a flow rate of 1.5 ml/min at a pressure of 80 kg/cm2. Fig. 1 shows the elution profile of nucleotide pools extracted from [2-14C]AZT-pretreated V-79 cells. Radioactivity eluted as 5'-mono-, 5'-di-, and 5'-triphosphates was quantitated by scintillation counting. The authenticity of the putative AZTMP, AZTDP, and AZTTP was demonstrated in a separate analysis in which fractions corresponding to these metabolites were collected, hydrolyzed for 40 min at 180°C in 88% formic acid to liberate free thymine, and analyzed by Aminex A-9 chromatography (20) . Radioactivity originally isolated as putative 5'-mono-, 5'-di-, and 5'-triphosphate forms of AZT was shown to be coeluted with free thymine, retaining the label originating at the 2-carbon of the pyrimidine ring of AZT (Fig. 1 Inset) . Thus, the radioactivity that was eluted within the nucleoside 5'-mono-, 5'-di-, and 5'-triphosphate regions of the original column procedure was shown to represent AZTMP, AZTDP, and AZTTP. Endogenous ATP was used as an internal standard. against the percent increase in DNA methylation (as compared with controls) occurring in cultures exposed to 100 and 150 ,uM AZT, it was seen that the induction of TK-epimutants was directly related to the degree of AZT-induced DNA hypermethylation over the dose range studied (Fig. 1 Inset) .
AZT-induced TK-clones 1-4 showed IC25 values of 122, 83, 190, and 128 ,M AZT, respectively, compared with an IC25 value of 30 ,uM for the TK+ parental cell line from which they were derived (Fig. 3 ). Upon challenge with 150 uM AZT, clones 1-4 showed 9-, 11-, 24-, and 10-fold increases, respectively, in resistance to AZT as compared with parental TK+ cells (Fig. 3) . Comparable increases in resistance to FdUrd were observed in these clones (Fig. 4) . Thus, clones To be effective as an antitumor agent or as a chain terminator for reverse transcription of HIV-i RNA genomes, AZT must be activated to AZTMP by the product of the cellular TK gene, and subsequently to AZTDP and AZTTP by the product of the thymidylate kinase gene. It was thus important for us to measure the capacity of our putative AZT-induced TK-epimutants to activate AZT to its proximate antitumor/antiviral form, AZTMP, and to AZTDP and AZTTP as well.
Nucleotide pool analysis (Fig. 5) showed that, with respect to activation to AZTMP, hypermethylation-induced clones showed levels corresponding to 4.2% (clone 1), 4.9% (clone 2), 0.8% (clone 3), and 0.6% (clone 4) of the parental TK+ cell line from which they were derived. Total AZTDP and AZTTP production was also reduced in the hypermethyla- (1 A,Ci/ml) for Transcriptional inactivation of the TK gene locus was responsible for the induction of AZT-resistant TK-epimutants (Table 2) . AZT-resistant clones 1-4 showed 8.9%, 15.6%, 17.8%, and 11.1% of the TK-specific mRNA found in an equivalent concentration (20 ,ug) of parental TK+ RNA. Following exposure to 5-azadC, levels of TK mRNA increased in the three revertible clones (nos. 1-3) to 84%, 51%, and 80% of the original TK+ parental cell-line level. These reactivation events represented increases in TK gene expression ranging from 3-to nearly 10-fold in the 5-azadC-induced revertants compared with the AZT-induced TK-epimutants from which they were derived.
All three 5-azadC-reactivated TK+ revertants showed a substantial increase in their ability to metabolize AZT, ranging from 3-fold to 34-fold at the 5'-monophosphate level, 2-fold to 15-fold at the diphosphate level, and zero to 2-fold at the triphosphate level, as compared with the TK-epimutants from which they were derived (Table 3) . Here again, the major change occurred at the monophosphate level rather than at the di-or triphosphate level, suggesting that TK and not thymidylate kinase represented the affected silenced (and reactivated) gene in this model system.
DISCUSSION
Previous work demonstrated that drug-induced DNA hypermethylation constitutes one response of cells to cytotoxic 11.1 Twenty micrograms of total RNA from each clone was blotted to nylon membrane and probed with an oligolabeled fragment from the 3' end of the Chinese hamster V-79 TK gene. Densitometric scans of the resulting films were quantitated by the method of peak heights. The level of TK mRNA expressed in the TK+ parental cell line was taken as 100lo of the expected expression level, and the values given above represent individual percentages of this level of expression. Clone 4 was not reactivatable by 5-azadC. Measurements of log(rot) indicated that the percent abundance of TK transcripts in the unsynchronized TK+ parental cell line analyzed in logarithmic phase was -0.5%. levels of DNA synthesis-inhibiting drugs, both in vitro and in vivo (19) (20) (21) . Since physiologic DNA methylation represents one mechanism by which cells silence genes (23) (24) (25) (26) , such drug-induced DNA hypermethylation may play a role in the development of resistance to drugs requiring metabolic activation (21) . In the present work we observed that at cytotoxic concentrations of AZT, a >2-fold enhancement in total genomic DNA methylation occurred in V-79 cells, concomitant with a 43-fold enhancement in the induction of AZT-resistant, TK-subclones compared with nontreated controls (Fig. 2) . (Under the conditions reported here, AZT resistance appeared to be primarily due to hypermethylation inactivation of the TK gene, rather than to inactivation of other genes whose protein products are also required for AZT activation-e.g., thymidylate kinase.) The IC25 value for AZT (Fig. 3) or FdUrd (Fig. 4) in these subclones was substantially increased and within a range that would confer drug resistance in vivo. Since three of four TK-AZTresistant subclones could be reactivated at high frequency for TK+ expression and resensitization towards AZT by exposure to the demethylating agent 5-azadC, the initial gene silencing clearly was an epigenetic rather than a mutational event in these three clones (Table 1) .
Occurring concomitantly with their loss of sensitivity to AZT or FdUrd, all drug-induced TK-epimutants lost their ability to activate AZT to its proximate antitumor/antiviral form, AZTMP (Fig. 5) . 5-azadC-induced reversion to the TK+ phenotype correlated directly with ability to reexpress TK-specific mRNA (Table 2 ) and the ability to activate AZT Medical Sciences: Nyce et al.
to AZTMP (Table 3 ). This finding suggests that drug-induced DNA hypermethylation occurring as part of the toxic response to drug exposure mimics the negative transcriptional regulation characteristic of physiologic DNA methylation. It can be noted from Figs. 2 and 3 that AZT is relatively nontoxic to V-79 cells, and very high levels of the drug (100-150 ,uM) were required to induce the toxicity of which DNA hypermethylation is a part. Drug-induced DNA hypermethylation very definitely is dependent upon toxic levels of drug exposure (21) . The levels of AZT used in our experiments are thus above those that can be achieved clinically (27) . However, the human CD4+ T-lymphocyte populations that are the target for AZT antiviral chemotherapy are much more sensitive to AZT than are V-79 cells. In fact, it has been demonstrated that human tissues in general are much more sensitive to AZT than are rodent tissues (28) . Further, with respect to anticancer chemotherapy, enhanced sensitivity to AZT might also be expected in human tumors expressing resistance to cisplatin by virtue of overexpression of TK or Pol genes (6) (7) (8) . That epigenetic events are indeed involved in establishing a drug-resistant state in vivo is supported by studies showing that lymphocytic leukemia cells resistant to araC, presumably by virtue of low expression of the required activating enzyme, deoxycytidine kinase, can be reactivated for deoxycytidine kinase expression and sensitivity to araC by exposure of patients to the demethylating agent 5-azacytidine (29) . This example of an apparently methylationrelated silencing of deoxycytidine kinase resulting in araC resistance in vivo bears striking similarity to TK gene silencing resulting in AZT resistance. Both drugs are false metabolites of DNA precursors and require metabolic activation to the nucleotide form for antitumor or antiviral action. Both possess chain-termination properties once they are incorporated into DNA. Finally, resistance to both drugs can occur by virtue of methylation silencing of the gene for the activating enzyme and can be reversed by exposure to demethylating agents. It therefore appears very likely that epigenetic gene-silencing events similar to those observed in araCtreated patients will also occur in patients undergoing anticancer or antiviral chemotherapy with AZT.
Mutations within the HIV-1 RT gene may confer resistance to AZT (3, 4) . The extent to which cell-mediated resistance to AZT contributes to the development of clinical resistance to AZT, either alone or in concert with viral RT gene mutations, remains to be determined. There is, however, some precedent for suggesting that optimum conditions for the development of RT gene mutations might exist within CD4+ T lymphocytes that have a methylation-silenced TK gene. Thus, in our hands, TK genes silenced by drug-induced DNA hypermethylation appear not to be totally silent. As illustrated in Fig. 5 and as observed by us in other experiments using V-79 and other cell types, residual TK activity in the range of 2-10o is common. Such limited activation of AZT to its proximate antiviral form in hypermethylationsilenced TK-epimutants may permit selective pressure sufficient to encourage viral evolution toward AZT-resistant subtypes, without being overtly lethal to the virus.
Finally, in order for AZT-induced DNA hypermethylation to silence TK genes under conditions which permit cell viability, repair of AZT-terminated replication intermediates must occur. Such repair of AZT-terminated replication intermediates has been reported in mammalian cells (30) .
Our results with the V-79 cell model system indicate that drug-induced DNA hypermethylation may play a role in the development of resistance to drugs requiring metabolic activation to their anticancer/antiviral forms. The contribution of such drug-induced DNA hypermethylation to in vivo drug resistance and the possibility and effects of its circumvention remain to be determined, however.
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